We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

EUROTROL

Eurotrol provides high specification, custom-made quality control (QC) materials for the periodic verification of the... read more Featured Products: More products

Download Mobile App





Eurotrol Highlights CueSee Range of Quality Control Materials for Critical Care, Laboratories and POC Sites

By LabMedica International staff writers
Posted on 28 Sep 2021

Eurotrol, Inc. More...

(Elizabethtown, KY, USA) highlighted its CueSee range of quality control materials for critical care, laboratories and point-of-care sites at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo which took place at the Georgia World Congress Center in Atlanta, September 26-30.

Eurotrol provides quality control materials with specialized formulations for critical care, laboratories and point-of-care sites in hospitals, clinics, proficiency testing providers, standardization bodies and instrument manufacturers (OEM). The company’s menu includes daily QC, calibration verification materials and standards.

At AACC 2021, Eurotrol demonstrated CueSee Ringe, an innovative, patented packaging concept that has modernized the in vitro diagnostics market. A special glass ampoule is sealed inside the CueSee Ringe device. This ampoule breaks with a simple turning motion without the risk of cutting fingers on glass particles or coming into contact with the liquid. After this activation step, the CueSee Ringe functions identically to a standard syringe. The liquid inside the ampoule is not deteriorated by environmental contamination, which reduces pre-analytical errors. This concept is ideal for solutions typically stored in ampoules for quality control, calibration verification, proficiency testing, competency assessment, method validations, and lot comparisons.

Eurotrol also demonstrated its CueSee VeriSTAT that offers complete quality control, cal/ver & reportable range validation for i-STAT test systems. Each liquid covers blood gasses, electrolytes & hematocrit over optimized ranges. Packaged in the new CueSee Ringe, the liquids will have extended open stability of more than five minutes and revolutionary safe opening and simple dosing. Also on display was CueSee Coag in CueSee Mix with its innovative packaging that separates the lyophilized material from the liquid until activation by a simple twist, resulting in a reliable POC Coag QC. CueSee Mix is an innovative dual-chambered device which separates fractions of QC material. CueSee Mix has many applications due to ease of use, no need for pipetting & reduction of matrix interactions – all in a single container. It is ideal for creating liquid matrixes that mimic human specimens & is suitable for QC, proficiency & competency testing, cal/ver & method validation. The CueSee Mix design led to the development of CueSee Coag a unique POC QC. The lyophilized material is kept separate from the liquid until activation by an easy twisting motion. After equilibration, the QC material is safely tested by use of the integrated dropper. CueSee Coag will be available in clinically significant ranges to ensure accurate patient results.

In addition, Eurotrol presented CueSee CO-OX in ACU-Drop II at the event. CueSee CO-OX is a QC for CO-oximeters with real hemoglobin derivatives. Its ACU-Drop II packaging provides long shelf life & ability to provide relevant ranges of all Hgb forms. The two chambered device separates the Hgb fractions until mixed by simply pushing a button. Sampling is easy with the integrated dropper or by attaching a syringe.

Related Links:
Eurotrol, Inc. 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








ADLM

Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.